Zetta Genomics is pleased to announce our participation in the PMFG Sidra Conference next week, a key gathering for the leaders shaping the next decade of genomics, precision medicine, and data-driven healthcare.
Representing Zetta Genomics at the event will be our Chief Commercial Officer, Mark Hughes, who will also be chairing a session during the event. Mark brings more than 25 years of experience in genomics and commercial strategy. At Zetta Genomics, he leads global commercial operations, and partnerships; working closely with large-scale genomic programmes to ensure they have the infrastructure they need to scale, integrate, and deliver precision medicine.
Showcasing Our New SaaS Products
This year marks an important milestone for Zetta Genomics as we expand our product offering with two new SaaS-first solutions, designed for teams that need immediate capability without the complexity of large platform deployments:
The XetaBase Variant Store: A secure, high-performance cloud-native repository for variant data, built to handle population-scale volumes. It provides harmonised, query-ready data structures that support fast clinical interpretation, cohort analysis, and downstream discovery.
The XetaBase Annotation Store: A powerful, continuously updated annotation engine that cross-references variants against multiple genomic knowledge bases. It ensures that teams always work from the most current and clinically relevant evidence, without needing to maintain their own workflows or infrastructure.
SaaS Point Solutions for Fast Adoption
To meet the needs of organisations looking for rapid, focused capability, Zetta Genomics now provides targeted point solutions powered by XetaBase. These lightweight solutions allow teams to adopt immediately impactful tools while retaining the option to expand into broader XetaBase capabilities as they grow.
Clinical Integrations: Streamlined connectivity with EHRs, LIMS, reporting tools and downstream clinical systems, enabling genomics to flow directly into clinical decision pathways.
Disease Risk Screening: Scalable pipelines for monogenic and polygenic risk screening, enabling early intervention and population-prevention programmes.
Pharmacogenomics (PGx): Robust PGx interpretation tools that integrate with clinical workflows, supporting safer prescribing and personalised treatment pathways.
XetaBase Version 4
We’re also delighted to be sharing more of our XetaBase Version 4 updates with the PMFG Sidra audience. These enhancements focus on improved performance, expanded multi-omics functionality, deeper clinical workflow integrations, and new capabilities designed specifically for large national and population-scale genomics initiatives. It’s an exciting step forward for our customers, and we’re thrilled to preview it with this esteemed group.
XetaBase is evolving to incorporate AI-driven modules that enhance speed, decision-making, and diagnostic efficiency across the pipeline.
Emerging capabilities include:
- AI-assisted variant prioritisation to reduce manual investigation time
- Evidence synthesis and summarisation for rapid interpretation
- Predictive analytics for disease insight and risk stratification
- Automated triage tools for clinical review
Each AI-enabled feature is designed to remain transparent, explainable, and compliant with clinical governance requirements, ensuring confidence in clinical and research settings.
XetaBase was designed from the outset to handle multi-omics at scale, including whole genome and exome sequencing, long-read data, transcriptomics, epigenomics, proteomics, and structural variants.
It supports federated multi-omics combinations for complex disease modelling, enabling researchers and clinicians to generate richer insights, accelerate biomarker discovery, and connect genotype to phenotype more effectively.
XetaBase Anywhere: Cloud or On-Premises Deployment
XetaBase is unique in offering full equivalence across cloud-native and on-prem infrastructures, without compromising performance or clinical standards, so that organisations can choose the infrastructure model that best fits their strategic and regulatory landscape.
On-prem XetaBase brings:
- Local control over data, access and governance
- Compliance with strict sovereignty requirements
- High performance for in-hospital or in-lab clinical workflows
- Deep system integration with existing secure networks, EHRs and LIMS
- Reliable long-term operational structure
Cloud-native XetaBase provides:
- Rapid deployment with minimal overhead
- Elastic scalability for large sequencing bursts
- Automatic updates for security and feature enhancements
- Lower operational burden for IT teams
- Ideal support for distributed networks such as national genomics programmes
Let’s Connect
If you’re attending the PMFG Sidra Conference, we would love to connect, either directly, or through one of our partners, IBM, GBM or Gulf Scientific, all of whom will be able to talk you through how we work together.
Please get in touch to schedule time with Mark (mark.hughes@zettagenomics.com) and ensure we don’t miss you during the event.
